Case Collection at Kellogg School of Management

Search by:

Name or Partial Name

Kellogg Case Collection

Business cases are one of a wide variety of teaching tools utilized by faculty at the Kellogg School of Management to enhance the learning experience of graduate students and Executive Education attendees alike. Students have the opportunity to apply theoretical learning, situation analysis, and decision-making skills in a safe classroom environment – yet it is intense practice for success in a challenging business environment.

The Kellogg School of Management is making available to academic practitioners and corporate trainers selected cases and teaching materials, developed by Kellogg faculty and taught in the Kellogg classroom.

For exercises from the Dispute Resolution Research Center (DRRC) and the Kellogg Team & Group Research Center (KTAG), please visit the DRRC Web site.

Search Results

Survivor Scios: Reality Biotech
Alicia Loffler; Liisa Bayko, 2004, Case #: 5-104-016 (KEL070)

This case describes the growth of a biotechnology company as it shifts from a service research organization to an integrated human therapeutic company. The case maps the management changes from 1982-1998 as the company responds to volatile market...

Bayer & Millennium Pharmaceuticals
Alicia Loffler; Marcus Solf; Edward Zajac, 2004, Case #: 5-104-014 (KEL068)

In the year 2000 Millennium Pharmaceuticals was the poster child for successful genomic companies. Millennium's fast growth and exuberant valuations were due to the elegant alliances the company had forged with top pharmaceutical, biotechnology, and...

Enbrel: The Sting of Success
Alicia Loffler; Geetha P Krishnan, 2004, Case #: 5-104-015 (KEL069)

Immunex, a small Seattle biotechnology company, stumbles into a hugely successful and groundbreaking product. Enbrel, a tumor necrosis factor, is immediately recognized as the most effective treatment for rheumatoid arthritis-a $300 billion market in the...

Genzyme: The Renvela Launch Decision
Timothy Calkins; Lynn Harris, 2009, Case #: 5-308-506 (KEL412)

Pharmaceutical company Genzyme has created a new drug, Renvela, which is a phosphate binder designed to be used primarily by patients with kidney failure. Renvela is a slightly different version of Genzyme’s highly successful Renagel. Company executives...

Balancing Access with Accuracy for Infant HIV Diagnostics in Tanzania (A)
Kara Palamountain; Sachin Waikar; Andrea Hanson; Katherine Nelson, 2008, Case #: 5-308-502(A) (KEL383)

The Global Health Initiative (GHI) is a tripartite collaboration among Northwestern University, non-profit donors, and commercial diagnostics companies. GHI attempts to bridge the gap between the market for sophisticated medical diagnostics...

Balancing Access with Accuracy for Infant HIV Diagnostics in Tanzania (B)
Kara Palamountain; Sachin Waikar; Andrea Hanson; Katherine Nelson, 2008, Case #: 5-308-502(B) (KEL384)

Merck: Pricing Gardasil
Timothy Calkins; Megha Vora, 2009, Case #: 5-308-505 (KEL400)

Allison Watkins, senior director of Merck’s Vaccines Division, needed to decide on the pricing of Gardasil, Merck’s newest vaccine and one of the company’s most important product launches of the year. The outside consulting firm she had hired to recommend...

Eli Lilly: Xigris (A)
Timothy Calkins; Karen White, 2004, Case #: 5-104-047(A) (KEL014)

This case examines the launch of Xigris, a breakthrough new pharmaceutical product for the treatment of sepsis. In the (A) case, the newly appointed head of marketing for Xigris is reviewing the launch plan. In the (B) case, Eli Lilly receives FDA...

Eli Lilly: Xigris (B)
Timothy Calkins; Karen White, 2004, Case #: 5-104-047(B) (KEL015)

MedImmune: FluMist Introduction
Timothy Calkins; Rajnish Changrani, 2004, Case #: 5-104-046 (KEL012)

This case examines the launch of FluMist, the first significant innovation in influenza vaccines in over fifty years. The head of sales and marketing for MedImmune is working through the launch plan for FluMist. In particular, he is struggling with the...

Myriad: Breast Cancer Testing in Britain (A)
Daniel Diermeier; Shobita Parthasarathy, 2004, Case #: 5-304-503(A) (KEL050)

The case describes Myriad Genetics and its struggle to secure exclusive testing services for the BRCA gene. After Myriad obtained licensing rights and dissolved its U.S. competition, it turned its focus to Europe, specifically the UK. The UK National...

ReintroduceThalidomide? (B)
Daniel Diermeier; Jason Hermitage; Shail Thaker; Justin Heinze, 2006, Case #: 5-104-003(B) (KEL059)

In the 1960s, Thalidomide, a popular new drug considered to be safe and effective, was revealed to cause severe nerve damage and birth defects in new-born infants, prompting health officials to ban the use of the drug and tighten overall restrictions on...

Reintroduce Thalidomide?(A)
Daniel Diermeier; Jason Hermitage; Shail Thaker; Justin Heinze, 2006, Case #: 5-104-003(A) (KEL058)

Zimmer: The Gender-Specific Knee
Timothy Calkins; Joseph Harmon, 2007, Case #: 5-207-252 (KEL276)

This case is focused on a simple question: should Zimmer develop a gender specific knee? The decision is complicated, because while the idea seems to make sense, there is little clinical evidence that a gender specific knee produces superior patient...

Innovation and Invention: A Patent Landscape
James Gerard Conley; David Orozco, 2006, Case #: 7-406-750 (KEL104)

The patent system is introduced to the non-legal professional by reviewing the historical justification for having a patent system and foundations of the U.S. patent system, contrasting patents with trade secrets, exploring invention requirements for...

Myriad: Breast Cancer Testing in the United States (A)
Daniel Diermeier; Shobita Parthasarathy, 2004, Case #: 5-304-504(A) (KEL052)

The case describes Myriad Genetics and its struggle to develop a genetic testing service while facing challenges from competitors and activist organizations. After Myriad’s discovery of the BRCA gene, capable of genetic testing for breast cancer in women,...

Intellectual Property: The Ground Rules
James Gerard Conley; David Orozco, 2005, Case #: 7-305-501 (KEL140)

Intellectual property rights are a major source of wealth creation in the modern global economy and continue to grow in significance. In order for managers and entreprenerus to appropriate the value of IP's strategic optionality, it is helpful to be...

Search by:

Search by keywords: